VS-6766+Abema+Fulv in Met HR+/HER- BC
VS-6766+Abema+Fulv in Met HR+/HER- BC
Recruiting · NCT05608252 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| VS-6766+Abema+Fulv in Met HR+/HER- BC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, hormone receptor-positive breast cancer, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-04-30 | NCT05608252 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Adrienne G. Waks | 3 |
| Eli Lilly and Company | 370 |
| Verastem, Inc. | 24 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana Farber Cancer Institite | Boston | United States | 4 |
| Massachusetts General Hospital Cancer Center | Boston | United States | 178 |